Advertisement

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Amit Sanyal, MD: A Clinician’s Perspective

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Advertisement

Advertisement




Dec
06
Today In Oncology
Study Identifies Rectal Bleeding as Key Predictor of Early-Onset Colorectal Cancer
Nivolumab and Ipilimumab in Advanced dMMR/MSI-H Noncolorectal Cancers
T-DXd Plus Pertuzumab in HER2-Positive Advanced or Metastatic Breast Cancer
AACR Pediatric Cancer Progress Report 2025
Camrelizumab Plus Rivoceranib vs Sorafenib for the First-Line Treatment of Unresectable Hepatocellular Carcinoma
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo